Streetbeat News

DNA

Ginkgo Bioworks Holdings, Inc.

https://www.ginkgobioworks.com

Industry

Biotechnology

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Open

8.30

Mkt cap

472M

Volume

498K

High

8.56

P/E Ratio

-0.47

52-wk high

75.20

Low

8.13

Div yield

N/A

52-wk low

5.26

Raymond James analyst Rahul Sarugaser has downgraded Ginkgo Bioworks Holdings (NYSE:DNA) from Outperform to Market Perform and set a price target of $2.5.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 4:51 pm

Raymond James analyst Rahul Sarugaser has downgraded Ginkgo Bioworks Holdings (NYSE:DNA) from Outperform to Market Perform and set a price target of $2.5.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 3:45 pm

The article lists the stocks that gained and lost the most in Thursday's mid-day session. Among the gainers were Intelligent Bio Solutions Inc., Astra Space, Inc., and Tempest Therapeutics, Inc., which saw significant increases due to positive quarterly results and acquisition proposals. Among the losers were Enviva Inc., ContraFect Corporation, and Atara Biotherapeutics, Inc., which saw significant decreases due to poor quarterly results and disappointing clinical trial outcomes.

Portfolio Pulse from Lisa Levin

November 09, 2023 | 6:13 pm

Ginkgo Bioworks reported mixed Q3 financial results, leading to a decrease in its stock value. Following the earnings report, BTIG downgraded the stock from Buy to Neutral.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 4:41 pm

BTIG analyst Mark Massaro has downgraded Ginkgo Bioworks Holdings (NYSE:DNA) from Buy to Neutral.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 2:32 pm

Ginkgo Bioworks Holdings (NYSE:DNA) reported Q3 losses of $(0.16) per share, missing the analyst consensus estimate of $(0.09) by 77.78%. However, the company's quarterly sales of $55.43 million beat the analyst consensus estimate of $48.08 million by 15.29%. This represents a 60.98% increase in losses and a 16.52% decrease in sales compared to the same period last year.

Portfolio Pulse from totan@benzinga.com

November 08, 2023 | 10:24 pm

Ginkgo Bioworks Holdings (NYSE:DNA) is set to release its latest quarterly earnings report on November 8, 2023. Analysts estimate an earnings per share (EPS) of $-0.09. The company's past performance shows a trend of missing EPS estimates, which has led to drops in share price. The company's shares are currently trading at $1.52 and have seen a 31.52% decrease over the last 52-week period.

Portfolio Pulse from Benzinga Insights

November 07, 2023 | 3:01 pm

Ginkgo BioWorks and XWELL are expanding their collaboration with the U.S. Centers for Disease Control and Prevention's traveler-based genomic surveillance program. They will now test for more than 30 additional priority pathogens, besides SARS-COV-2.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 12:15 pm

Ginkgo Bioworks (NYSE:DNA) and the Government of Serbia have announced a Memorandum of Understanding (MoU) to collaborate in support of Serbia's bioeconomy vision. The partnership will establish a Startup Accelerator that leverages Ginkgo's platform and expertise to support Serbian companies in the bioeconomy sector. The collaboration will also explore partnerships to develop and implement new biomonitoring capabilities in Serbia. Companies at Serbia's BIO4 campus will have opportunities to engage Ginkgo staff and access Ginkgo expertise on site.

Portfolio Pulse from Benzinga Newsdesk

October 19, 2023 | 8:02 pm

QL AG has entered into a collaboration with Ginkgo Bioworks to develop dairy proteins. QL AG will leverage Ginkgo's strain engineering capabilities to provide the market with high-quality, nutritionally equivalent dairy proteins.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 11:03 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.